Effect of losartan and benzbromarone on the level of human urate transporter 1 mRNA

Arzneimittel-Forschung/Drug Research

Volumn 60, Issue 4, 2010, Pages 186-188

  Nindita, Yora ^a,b   Hamada, Toshihiro ^c   Bahrudin, Udin ^a,b   Hosoyamada, Makoto ^d   Ichida, Kimiyoshi ^e   Iwai, Chisato ^a   Urashima, Sunao ^a   Kuwabara, Narimasa ^a   Utami, Sulistiyati Bayu ^a   Mizuta, Einosuke ^c   Yamada, Kensaku ^c   Igawa, Osamu ^c   Shigemasa, Chiaki ^c   Ninomiya, Haruaki ^c   Tsuchihashi, Takuya ^f   Hisatome, Ichiro ^a  

^a TOTTORI UNIVERSITY   (Japan)

^b DIPONEGORO UNIVERSITY   (Indonesia)

^c TOTTORI UNIVERSITY   (Japan)

^d KEIO UNIVERSITY   (Japan)

^e TOKYO UNIVERSITY OF PHARMACY AND LIFE SCIENCES   (Japan)

^f NATIONAL HOSPITAL ORGANIZATION KYUSHU MEDICAL CENTER   (Japan)

Author keywords

Benzbromarone; CAS 124750 99 8; CAS 3562 84 3; Human urate transporter 1 mRNA; Losartan

Indexed keywords

BENZBROMARONE; CAS 124750 99 8; CAS 3562 84 3; LOSARTAN; MESSENGER RNA; UNCLASSIFIED DRUG; URATE; URATE TRANSPORTER 1;

ARTICLE; CELL STRAIN HEK293; CONTROLLED STUDY; EMBRYO; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; HYPERTENSION; REDUCTION;

EID: 77951761105     PISSN: 00044172     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-0031-1296271     Document Type: Article

References (15)

1. Nakashima M, Uematsu T, Kosuge K and Kanamaru M. Pilot study of the uricosuric effect of DuP-753, a new angiotensin II receptor antagonist, in healthy subjects. Eur J Clin Pharmacol. 1992;42:333-335
2. Edwards RM, Trizna W, Stack EJ, Weinstock J. Interaction of nonpeptide angiotensin II receptor antagonists with the urate transport in rat renal brush-border membranes. J Pharmacol Exp Ther. 1996;276:125-129 (Pubitemid 26151535)
3. Puig JG, Mateos F, Buno A, Ortega R, Rodriguez F, Dal-Fe R. Effect of eposartan and losartan on uric acid metabolism in patients with essential hypertension. J Hypertens. 1999;17:1033-1039 (Pubitemid 29322193)
4. Hamada T, Hisatome I, Kinugasa Y, Matsubara K, Shimizu H, Tanaka H, et al. Effect of the angiotensin II receptor antagonist losartan on uric acid and oxypurine metabolism in healthy subjects. Intern Med. 2002;41:793-797 (Pubitemid 35314777)
5. Buriner M, Roch-Ramel F, Brunner HR. Renal effects of angiotensin II receptor blockade in normotensive subjects. Kidney Int. 1996;49:1787-1790 (Pubitemid 26186613)
6. Roch-Ramel F, Guisan B, Diezi J. Effects of uricosuric and antiuricosuric agents on urate transport in human brush-border membrane vesicles. J Pharmacol Exp Ther. 1997;280:839-845 (Pubitemid 27171347)
7. Enomoto A, Kimura H, Chairoungdua A, Shigeta Y, Jutabha P, Cha SH, et al. Molecular identification of a renal urateanion exchanger that regulates blood urate levels. Nature. 2002;417:447-452 (Pubitemid 34563537)
8. Iwanaga T, Sato M, Maeda T, Ogihara T, Tamai I. Concentration-dependent mode of interaction of angiotensin II receptor blockers with uric acid transporter. J Pharmacol Exp Ther. 2007;320:211-217 (Pubitemid 46025736)
9. Hamada T, Ichida K, Hosoyamada M, Mizuta E, Yanagihara K, Sonoyama K, et al. Uridosuric action of losartan via inhibition of urate transporter (URAT1) in hypertensive patients. Am J Hypertens. 2008;21:1157-1162.
10. Levinson DJ, Sorensen LB. Renal handling of uric acid in normal and gouty subjects: evidence for a 4-component system. Ann Rheum Dis. 1980;39:173-179.
11. Ichida K, Hosoyamada M, Hisatome I, Enomoto A, Hikita M, Endou H, et al. Clinical and molecular analysis of patients with renal hypouricemia in Japan - Influence of URAT1 gene on urinary urate excretion. J Am Soc Nephrol. 2004;15:164-173 (Pubitemid 38020708)
12. Rafey MA, Lipkowitz MS, Leal-Pinto E, Abramson RG. Uric acid transport. Curr Opin Nephrol Hypertens. 2003;12:511-516
13. Imaoka T, Kusuhara H, Adachi-Akahane S, Hasegawa M, Morita N, Endou H, et al. The renal-specific transporter mediates facilitative transport of organic anions at the brush border membrane of mouse renal tubules. J Am Soc Nephrol. 2004;15: 2012-2022 (Pubitemid 39031340)
14. Enomoto A, Endou H. Roles of organic anion transporters (OATs) and a urate transporter (URAT1) in the pathophysiology of human disease. Clin Exp Nephrol. 2005;9:195-205. (Pubitemid 41414118)
15. Naritomi H, Fujita T, Ito S, Ogihara T, Shimada K, Shimamoto K, et al. Efficacy and safety of long-term losartan therapy demonstrated by a protective observational study in Japanese patients with hypertension: The Japanese Hypertension Evaluation with Angiotensin II Antagonist Losaratan Therapy (J-HEALTH) study. Hypertens Res. 2008;31:295-304. (Pubitemid 351461110)